Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background.
Nurphoto | Nurphoto | Getty Images
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.
The company’s stock was down 5.4% at 11:22 a.m. London time.
Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy, previously forecast weight loss of 25% for patients who take CagriSema. In another late-trial result published in December, the company found CagriSema helped patients reduce their weight by 22.7% in that test.
CagriSema is being investigated by Novo Nordisk as a weight-loss drug for adults who are overweight or obese, as well as a treatment for adults with type 2 diabetes. The company currently expects to file for regulatory approval for CagriSema in the first quarter of 2026.
This breaking news story is being updated.